-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $24

Benzinga·01/09/2026 14:09:23
Listen to the news
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $24.